Poor
Mostly Unaligned
Patient Risk:
Low
Summary
Most claims concern pricing/insurance/pharmacy behavior and savings/discount programs, none of which are supported by the provided FDA label sections. Only the active-ingredient/identity portion is partially supported by labeling in Description.
Category Scores
Accurate Statements
Pradaxa is dabigatran.
Label Section 11 (Description) describes PRADAXA contains dabigatran etexilate mesylate and states the ester is hydrolyzed to form dabigatran (active moiety).
Unsupported Statements
Generic pricing for dabigatran differs by dose strength.
No pricing or market-behavior information is present in the provided label sections.
Prices vary by strength (dose), tablet count, pharmacy, and location.
No pricing determinants (strength, tablet count, pharmacy, location) are described in provided label sections.
Out-of-pocket cost depends on exact dose, pharmacy, and whether the drug is covered by insurance and the insurance tier.
The provided label sections do not discuss out-of-pocket costs, insurance coverage rules, or insurance tiers.
Even after a generic launches, some pharmacies may price it closer to the brand early on.
No post-launch pharmacy pricing behavior is described in provided label sections.
Coverage rules can keep a copay high even after a generic launches.
No copay/coverage rules are described in provided label sections.
Availability of dabigatran varies by strength and form.
The provided label sections do not describe availability by strength or formulation beyond listing capsule strengths in Description.
Manufacturer savings programs may reduce the price when available and applicable.
No manufacturer savings program or price-reduction program information is present in provided label sections.
Pharmacy discount programs may reduce the price.
No pharmacy discount program information is present in provided label sections.
Insurance copay management may reduce the price.
No insurance copay management program information is present in provided label sections.
Contradictions
Important Omissions
Label-supported safety/clinical content (e.g., contraindications, warnings/precautions, dosing/administration, drug interactions, monitoring) is not addressed by the evaluated response claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims relate to economic/availability topics rather than dosing or safety; however, they are not label-grounded and thus may mislead about cost/access.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Multiple statements about pricing, insurance coverage/coplay dynamics, pharmacy behavior, and discount programs are not present in the FDA label sections provided, making the response largely non-on-label.
Suggested Improvement
Limit claims to label-supported information (e.g., active moiety identity and listed capsule strengths in Description) and remove all economic/access/pricing/discount-related assertions unless supported by the provided labeling.